Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The mean age of the 30 acromegaly patients (M/F:14/16) was 47.26 ± 12.52 years (range: 18-64 years) and that of the healthy volunteers (M/F: 17/13) was 44.56 ± 10.74 years (range: 19-62 years).Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels were measured using an electrochemiluminescence method, and serum sclerostin levels using an enzyme-linked immunosorbent assay.The Mann-Whitney U test was used to compare sclerostin levels between the two groups.
|
31821453 |
2020 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Achieving biochemical control (normalization of insulin-like growth factor-1 [IGF-1] and growth hormone [GH]) is a key goal in acromegaly management.
|
31741320 |
2020 |
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Suppressor of cytokine signaling (SOCS) 2, a negative regulator of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), which is associated with acromegaly and cancers, is a promising candidate molecule for treating various diseases.
|
30343638 |
2019 |
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Growth hormone (GH) secreting pituitary adenomas are the main cause of acromegaly.
|
30986651 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a rare disease due to chronic excess growth hormone (GH) and IGF-1.
|
30851160 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silent somatotroph pituitary neuroendocrine tumors (or silent growth hormone pituitary neuroendocrine tumors, SGH-PitNET) are neoplasias with positive immunostaining for growth hormone (GH), in patients with no signs and symptoms of acromegaly nor biochemical evidence of GH hypersecretion.
|
30531696 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Discuss the different diseases that present with manifestations of GH excess and clinical acromegaly, emphasizing the distinct clinical and radiological characteristics of the different pathological entities.
|
31766255 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is associated with increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) secretion which may support tumour development and growth.
|
30742299 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
The high expression of somatostatin receptor 2 (SST2) in growth hormone (GH)-secreting tumors represents the rationale for the clinical use of somatostatin analogs (SSAs) in acromegaly.
|
31574507 |
2019 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate FGF-21 levels in acromegaly which is characterized by excess GH levels and is associated with comorbidities and altered body composition.
|
29754168 |
2019 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acromegaly is a rare disease characterized by high levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
|
30482010 |
2019 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although not statistically significant, higher growth hormone levels, more elevated Ki-67 expression, greater somatostatin receptor (SSTR) subtype 5 expression, and lower SSTR subtype 2 expression at the diagnosis of acromegaly were detected in patients receiving combination treatment with pasireotide and pegvisomant compared with the control group.
|
31219586 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
The ML-based qTA of T2-weighted MRI is a potential non-invasive tool in predicting response to SAs in patients with acromegaly and GH-secreting pituitary macroadenoma.
|
30506213 |
2019 |
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the pathophysiology of endothelial dysfunction in the condition of GH and IGF-1 excess remains a crucial area of investigation to fully dissect the association of acromegaly with cardiovascular disease complications.
|
31396153 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
A better understanding of the dynamics mediating GH response to glucose may allow a more optimal use of the OGTT as a diagnostic tool in various conditions, especially acromegaly.
|
30685760 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present review, we elucidate the effects of GH hypersecretion on metabolic organs, describing the pathophysiology of impaired glucose tolerance in acromegaly, as well as the impact of acromegaly-specific therapies on glucose metabolism.
|
31417493 |
2019 |
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Acromegaly was suspected due to her facial features, and subsequent examinations revealed the presence of GH excess with a pituitary tumor, leading to the diagnosis of acromegaly.
|
31189769 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
This is a retrospective cohort study of patients with acromegaly (G1, n = 40) and a group in whom acromegaly was not confirmed (G2, n = 53) who had OGTT-GH suppression test during 2000-2012, using a monoclonal GH immunoenzymatic assay.
|
30415402 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
As growth hormone (GH) and triiodothyronine (T<sub>3</sub>) increase both GFR and CysC (increased in acromegaly and hyperthyroidism) in vivo, we studied whether they could increase CysC production in 3T3-L1 adipocytes in vitro.
|
30543877 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a rare disorder resulting from benign growth hormone (GH)-secreting pituitary adenomas in 90% of the cases.
|
31372169 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
In adults, hypersecretion of GH causes acromegaly, and strategies that block the release of GH or that inhibit GH receptor (GHR) activation are the primary forms of medical therapy for this disease.
|
30775002 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Growth hormone (GH) plays a significant role in normal renal function and overactive GH signaling has been implicated in proteinuria in diabetes and acromegaly.
|
31511328 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using a modern sensitive GH assay, GHnadir concentrations in healthy subjects are distinctly lower than cut-offs used in previous guidelines for diagnosis and monitoring of acromegaly.
|
31096183 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our understanding of the cellular and molecular effects of GH in the pathogenesis of renal complications of diabetes and acromegaly has significantly progressed in recent years.
|
30394899 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings indicate that low levels of BCAAs represent the main metabolic fingerprint of acromegaly and that GH, rather than IGF-1, might be the primary mediator.
|
31561638 |
2019 |